Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Benign prostatic hyperplasia: challenges for the new millennium.

M A Cabelin1, A E Te, S A Kaplan

  • 1Department of Urology, J. Bentley Squier Urological Clinic, New York Presbyterian Hospital, Columbia Medical Center, NY, USA. mcabelin@earthlink.net

Current Opinion in Urology
|August 5, 2000
PubMed
Summary

Benign prostatic hyperplasia (BPH) management is evolving, requiring better understanding of its molecular basis and improved outcome measures. Research is needed to evaluate new minimally invasive prostate therapies against traditional treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Cell communication and signaling : CCS·2021
Same author

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.

International journal of clinical practice·2014
Same author

Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors.

Drugs & aging·2014
Same author

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH.

Current bladder dysfunction reports·2013
Same author

Systematic review of the relationship between bladder and bowel function: implications for patient management.

International journal of clinical practice·2013
Same author

A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.

International journal of clinical practice·2012

Area of Science:

  • Urology
  • Andrology
  • Molecular Biology

Background:

  • Benign prostatic hyperplasia (BPH) and its associated lower urinary tract symptoms (LUTS) present complex diagnostic and therapeutic challenges.
  • Current understanding of BPH pathophysiology, including molecular mechanisms and growth factors, requires further elucidation.
  • Existing disease classifications and symptom scores for BPH are improving but need to better incorporate patient-reported outcomes like 'bother' and quality of life.

Purpose of the Study:

  • To review the evolving landscape of benign prostatic hyperplasia (BPH) understanding and therapy.
  • To highlight the need for enhanced diagnostic markers and the role of urodynamics in guiding treatment selection.
  • To discuss advancements in medical and minimally invasive therapies for BPH.

Main Methods:

Related Experiment Videos

  • Literature review of recent advancements in BPH understanding and treatment.
  • Analysis of current diagnostic and therapeutic approaches, including medical and surgical interventions.
  • Emphasis on the need for prospective, multicenter studies to compare new technologies with standard care.

Main Results:

  • Medical therapy for BPH has expanded, but further research is warranted.
  • Minimally invasive prostate therapies represent a significant area of growth and innovation.
  • Current clinical evaluation and laboratory markers for BPH/LUTS are insufficient.

Conclusions:

  • A comprehensive understanding of BPH molecular mechanisms is crucial for advancing therapy.
  • Urodynamic evaluation remains vital for guiding treatment decisions in BPH management.
  • Long-term comparative studies are essential to validate the efficacy of novel BPH technologies against established procedures.